About Mono Pharmacare
Mono Pharmacare is a publicly listed company based in Ahmedabad (India) founded in 2022. Diversified pharmaceutical drugs are distributed across Indian markets. The company has 65 employees. Its Indian entity Mono Pharmacare Limited reported revenue of ₹166 Cr. Mono Pharmacare offers products and services including Antibiotic Medicines, Cough and Cold Medicines, Antifungal Medicines, Analgesic and Antipyretic Medicines, and Nutraceutical Products. Its focus areas include Pharmaceutical Distributors and Diversified. Similar companies include Entero Healthcare, Keimed and Sandor Medicaids; 3 of its 3 listed similar companies have raised funding.
Company details
Mono Pharmacare was established in 2022 in Ahmedabad, India, within the pharmaceutical sector. Diversified drugs are distributed by the company to various healthcare providers and retailers. Operations focus on supply chain management and regulatory compliance in the Indian market. Services include procurement, storage, and timely delivery of essential medications. The domain monopharmacareltd.com supports online inquiries and business interactions.
- Headquarters Ahmedabad, India
- Employees 65
- Stage Public
- SectorsHealthcare
- Website monopharmacareltd.com
- Social LinkedIn X Facebook Instagram
- Legal Name Mono Pharmacare Limited
- Market Cap₹18.11 Cr
MONOPHARMA-SM · NSE
- Share Price₹10.25
0.00% today
- Revenue₹166 Cr
FY 2025-26 · -1.6% YoY
- EBITDA₹3.99 Cr
Margin 2.4%
- Net Profit₹0.34 Cr
FY 2025-26 · -88.9% YoY
- P/E (TTM)24.7x
P/B 0.6x
- Employee Count65
Associated legal entities of Mono Pharmacare
Mono Pharmacare operates through Mono Pharmacare Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Mono Pharmacare Limited Listed CIN L24304GJ2022PLC136193 | Active | 17 Oct 2022 | Ahmedabad, Gujarat | ₹166 Cr | 65 | 6 | View details |
Products & Services of Mono Pharmacare
Mono Pharmacare offers a comprehensive portfolio of products and services, including Antibiotic Medicines, Cough and Cold Medicines, Antifungal Medicines, Analgesic and Antipyretic Medicines, and Nutraceutical Products.
Medications to treat bacterial infections effectively.
Relieve symptoms of cough, cold, and allergies.
Solutions for various types of fungal infections.
Provide pain relief and reduce fever symptoms.
Supplements to support body revitalization and mind health.
Board of directors of Mono Pharmacare Limited (Mono Pharmacare)
Mono Pharmacare Limited is the primary company behind Mono Pharmacare. The board of Mono Pharmacare Limited currently have 5 directors; the longest-serving is Panilam Lakhatariya, appointed in 2022. 6 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Panilam Lakhatariya DIN 07659275 | Managing Director | 17 Oct 2022 | 4 yrs | Mono Pharmacare Limited |
| Supal Panilam Lakhatariya DIN 07659180 | Director | 17 Oct 2022 | 4 yrs | Mono Pharmacare Limited |
| Chintan Trivedi DIN 10074674 | Director | 22 Mar 2023 | 3 yrs 7 mo | Mono Pharmacare Limited |
| Drashti Rohit Chande DIN 10380640 | Director | 11 Jan 2025 | 1 yr 10 mo | Mono Pharmacare Limited |
| Nirmala Ranawat DIN 11309088 | Director | 03 Jun 2026 | 5 mo | Mono Pharmacare Limited |
IPO & Listings of Mono Pharmacare
Mono Pharmacare is a publicly listed company on the NSE with ticker symbol MONOPHARMA in India, operating in the Distribution services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date07 Sep 2023
- Listed onNSE: MONOPHARMA
- Listed entityMono Pharmacare Limited
- Exchange sectorDistribution services
- ISININE0OIP01012
- Share price₹8.90 (+4.71% on the day) · 2026-10-09
- Market capitalisation₹15.7 Cr
- Price to earnings44.6
- EPS (diluted, trailing year)₹0.20
- Volume (last session)14,000
Financials of Mono Pharmacare
Exchange-reported figures of Mono Pharmacare Limited, the listed company behind Mono Pharmacare (NSE: MONOPHARMA-SM).
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 166 | 168 | 122 | 33.09 |
| Revenue growth | -1.6% | +37.6% | +269.7% | - |
| EBITDA | 3.99 | 7.63 | 6.33 | 2.25 |
| EBITDA margin | +2.4% | +4.5% | +5.2% | +6.8% |
| Profit before tax | 0.57 | 4.45 | 3.23 | 1.33 |
| Net profit | 0.34 | 3.07 | 2.44 | 0.95 |
| Net profit margin | +0.2% | +1.8% | +2.0% | +2.9% |
| EPS (₹) | 0.20 | 1.75 | 1.38 | 1.53 |
| Balance sheet | ||||
| Total assets | 88.21 | 84.88 | 69.61 | 53.62 |
| Net worth | 31.55 | 31.20 | 28.11 | 13.69 |
| Total debt | 56.50 | 53.56 | 41.44 | 39.93 |
| Cash & bank | 0.98 | 0.70 | 0.36 | 0.42 |
| Net working capital | 87.22 | 83.82 | 68.66 | 52.16 |
| Cash flow | ||||
| Cash from operations | 2.68 | (4.30) | (8.77) | (39.54) |
| Cash from investing | (0.38) | (0.23) | 0.40 | (1.16) |
| Cash from financing | (2.01) | 4.86 | 8.32 | 40.73 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 92.91 | 82.64 | 70.72 | 13.92 |
| Revenue growth | +12.4% | +16.9% | +408.1% | - |
| EBITDA | 2.04 | 2.57 | 2.45 | 0.88 |
| EBITDA margin | +2.2% | +3.1% | +3.5% | +6.3% |
| Profit before tax | 0.42 | 3.79 | 2.86 | 0.68 |
| Net profit | 0.34 | 3.10 | 2.44 | 0.55 |
| Net profit margin | +0.4% | +3.8% | +3.5% | +4.0% |
| EPS (₹) | 0.20 | 1.75 | 1.38 | 0.44 |
| Balance sheet | ||||
| Total assets | 58.38 | 54.98 | 41.42 | 25.90 |
| Net worth | 31.55 | 31.20 | 28.11 | 13.40 |
| Total debt | 26.70 | 23.69 | 13.27 | 12.51 |
| Cash & bank | 0.35 | 0.11 | 0.25 | 0.23 |
| Net working capital | 47.29 | 43.85 | 37.66 | 23.68 |
| Cash flow | ||||
| Cash from operations | 0.73 | (0.73) | (10.32) | (13.49) |
| Cash from investing | 0.01 | (7.43) | (1.66) | (2.18) |
| Cash from financing | (0.50) | 8.02 | 12.00 | 15.90 |
Financial Statements
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Revenue | 166 | 168 | 122 | 33.09 |
| Revenue growth | -1.6% | +37.6% | +269.7% | - |
| Other income | 0.01 | 0.98 | 0.10 | 0.06 |
| Total expenses | 162 | 161 | 116 | 30.84 |
| Employee cost | 0.00 | 2.90 | 2.62 | 0.75 |
| EBITDA | 3.99 | 7.63 | 6.33 | 2.25 |
| EBITDA margin | +2.4% | +4.5% | +5.2% | +6.8% |
| Depreciation | 0.11 | 0.13 | 0.12 | 0.05 |
| Interest | 3.32 | 4.03 | 3.08 | 0.93 |
| Profit before tax | 0.57 | 4.45 | 3.23 | 1.33 |
| Tax | 0.23 | 1.36 | 0.77 | 0.38 |
| Net profit | 0.34 | 3.07 | 2.44 | 0.95 |
| Net profit margin | +0.2% | +1.8% | +2.0% | +2.9% |
| EPS (₹) | 0.20 | 1.75 | 1.38 | 1.53 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Equity & liabilities | ||||
| Share capital | 17.67 | 17.67 | 17.67 | 12.37 |
| Reserves & surplus | 13.88 | 13.53 | 10.44 | 1.32 |
| Shareholders' funds (net worth) | 31.55 | 31.20 | 28.11 | 13.69 |
| Minority interest | 0.04 | 0.04 | 0.02 | 0.00 |
| Secured loans | 28.58 | 29.88 | 23.86 | 26.83 |
| Unsecured loans | 27.92 | 23.68 | 17.58 | 13.10 |
| Total debt | 56.50 | 53.56 | 41.44 | 39.93 |
| Total liabilities | 88.21 | 84.88 | 69.61 | 53.62 |
| Assets | ||||
| Gross block | 1.38 | 1.38 | 1.17 | 0.99 |
| Net block | 0.88 | 0.99 | 0.91 | 0.83 |
| Capital work in progress | 0.02 | 0.02 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.57 |
| Inventories | 42.43 | 55.39 | 42.29 | 32.69 |
| Sundry debtors | 74.94 | 41.89 | 31.59 | 21.87 |
| Cash & bank balances | 0.98 | 0.70 | 0.36 | 0.42 |
| Loans & advances | 2.95 | 11.02 | 5.92 | 6.14 |
| Total current assets | 121 | 109 | 80.16 | 61.12 |
| Total current liabilities | 34.08 | 25.18 | 11.50 | 8.96 |
| Net working capital | 87.22 | 83.82 | 68.66 | 52.16 |
| Total assets | 88.21 | 84.88 | 69.61 | 53.62 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Opening cash | 0.70 | 0.36 | 0.42 | 0.38 |
| Net cash from operating activities | 2.68 | (4.30) | (8.77) | (39.54) |
| Net cash from investing activities | (0.38) | (0.23) | 0.40 | (1.16) |
| Net cash from financing activities | (2.01) | 4.86 | 8.32 | 40.73 |
| Net change in cash | 0.29 | 0.33 | (0.06) | 0.04 |
| Closing cash | 0.98 | 0.70 | 0.36 | 0.42 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Growth | ||||
| Sales growth | -1.6% | +37.6% | +269.7% | - |
| EBITDA growth | -47.7% | +20.5% | +181.3% | - |
| PBT growth | -87.2% | +37.8% | +21.4% | +9997.0% |
| Net income growth | -88.9% | +25.8% | +156.8% | - |
| Revenue CAGR (3Y) | +71.1% | - | - | - |
| EBITDA CAGR (3Y) | +21.0% | - | - | - |
| Profitability & leverage | ||||
| Net income margin | +0.2% | +1.8% | +2.0% | +2.9% |
| Return on capital employed | - | +11.0% | +10.2% | +8.4% |
| Return on net worth | - | +10.5% | +11.8% | +13.9% |
| Debt / equity | - | 1.60 | 1.95 | 2.92 |
| Long-term debt / equity | - | 0.73 | 0.71 | 0.91 |
| Interest cover | 85.57 | 53.73 | 49.60 | 42.27 |
| Efficiency & per share | ||||
| Fixed asset turnover | - | 132.03 | 113.28 | 66.85 |
| Inventory turnover | - | 3.45 | 3.26 | 2.02 |
| Debtors turnover | - | 4.58 | 4.58 | 3.03 |
| EPS (₹) | 0.20 | 1.75 | 1.38 | 1.53 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 17.66 | 15.91 | 11.06 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Revenue | 92.91 | 82.64 | 70.72 | 13.92 |
| Revenue growth | +12.4% | +16.9% | +408.1% | - |
| Other income | 0.00 | 2.54 | 1.70 | 0.20 |
| Total expenses | 90.87 | 80.07 | 68.27 | 13.04 |
| Employee cost | 0.00 | 2.38 | 2.15 | 0.50 |
| EBITDA | 2.04 | 2.57 | 2.45 | 0.88 |
| EBITDA margin | +2.2% | +3.1% | +3.5% | +6.3% |
| Depreciation | 0.08 | 0.08 | 0.08 | 0.02 |
| Interest | 1.54 | 1.24 | 1.21 | 0.38 |
| Profit before tax | 0.42 | 3.79 | 2.86 | 0.68 |
| Tax | 0.08 | 0.69 | 0.42 | 0.13 |
| Net profit | 0.34 | 3.10 | 2.44 | 0.55 |
| Net profit margin | +0.4% | +3.8% | +3.5% | +4.0% |
| EPS (₹) | 0.20 | 1.75 | 1.38 | 0.44 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Equity & liabilities | ||||
| Share capital | 17.67 | 17.67 | 17.67 | 12.37 |
| Reserves & surplus | 13.88 | 13.53 | 10.44 | 1.03 |
| Shareholders' funds (net worth) | 31.55 | 31.20 | 28.11 | 13.40 |
| Secured loans | 10.91 | 11.80 | 13.16 | 10.00 |
| Unsecured loans | 15.79 | 11.89 | 0.11 | 2.51 |
| Total debt | 26.70 | 23.69 | 13.27 | 12.51 |
| Total liabilities | 58.38 | 54.98 | 41.42 | 25.90 |
| Assets | ||||
| Gross block | 0.41 | 0.41 | 0.24 | 0.21 |
| Net block | 0.15 | 0.23 | 0.14 | 0.19 |
| Capital work in progress | 0.02 | 0.02 | 0.00 | 0.00 |
| Investments | 10.83 | 10.84 | 3.59 | 1.97 |
| Inventories | 25.04 | 27.79 | 20.99 | 15.18 |
| Sundry debtors | 39.90 | 18.90 | 17.44 | 8.08 |
| Cash & bank balances | 0.35 | 0.11 | 0.25 | 0.23 |
| Loans & advances | 1.23 | 8.14 | 2.96 | 3.35 |
| Total current assets | 66.52 | 54.94 | 41.64 | 26.84 |
| Total current liabilities | 19.23 | 11.09 | 3.98 | 3.16 |
| Net working capital | 47.29 | 43.85 | 37.66 | 23.68 |
| Total assets | 58.38 | 54.98 | 41.42 | 25.90 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Opening cash | 0.11 | 0.25 | 0.23 | 0.00 |
| Net cash from operating activities | 0.73 | (0.73) | (10.32) | (13.49) |
| Net cash from investing activities | 0.01 | (7.43) | (1.66) | (2.18) |
| Net cash from financing activities | (0.50) | 8.02 | 12.00 | 15.90 |
| Net change in cash | 0.24 | (0.14) | 0.02 | 0.23 |
| Closing cash | 0.35 | 0.11 | 0.25 | 0.23 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Growth | ||||
| Sales growth | +12.4% | +16.9% | +408.1% | - |
| EBITDA growth | -20.6% | +4.9% | +178.4% | - |
| PBT growth | -88.9% | +32.5% | +320.6% | +9997.0% |
| Net income growth | -89.0% | +27.1% | +343.6% | - |
| Revenue CAGR (3Y) | +88.3% | - | - | - |
| EBITDA CAGR (3Y) | +32.4% | - | - | - |
| Profitability & leverage | ||||
| Net income margin | +0.4% | +3.8% | +3.5% | +4.0% |
| Return on capital employed | - | +10.4% | +12.1% | +4.0% |
| Return on net worth | - | +10.4% | +11.8% | +4.0% |
| Debt / equity | - | 0.62 | 0.62 | 0.93 |
| Long-term debt / equity | - | 0.30 | 0.15 | 0.16 |
| Interest cover | 78.57 | 49.80 | 51.05 | 44.19 |
| Efficiency & per share | ||||
| Fixed asset turnover | - | 254.28 | 314.31 | 66.29 |
| Inventory turnover | - | 3.39 | 3.91 | 0.92 |
| Debtors turnover | - | 4.55 | 5.54 | 1.72 |
| EPS (₹) | 0.20 | 1.75 | 1.38 | 0.44 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 17.66 | 15.91 | 10.83 |
Similar companies to Mono Pharmacare
Mono Pharmacare has 3 listed similar companies in our database, 3 of them funded. They include Entero Healthcare, Keimed and Sandor Medicaids.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| enterohealthcare.com | 2018 | Mumbai, India | $59.67M | 817 | India's leading healthcare products distribution platform | |
| keimed.com | 2000 | Hyderabad, India | $16.62M | 588 | Temperature-sensitive medicines are distributed via cold chain logistics by Keimed. | |
| sandor.co.in | 1995 | Hyderabad, India | $8.98M | 161 | Provider of medical equipment, devices, and drugs distribution services |
Detailed similar companies of Mono Pharmacare
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Mono Pharmacare
The website of Mono Pharmacare (monopharmacareltd.com) receives about 1K visits a month.
- Monthly visits1K
▼ 62.1% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Mono Pharmacare
Complete news archive for Mono Pharmacare
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mono Pharmacare
Mono Pharmacare was founded in 2022.
Mono Pharmacare is headquartered in Ahmedabad, India. It is registered at Ahmedabad, Gujarat, India.
Mono Pharmacare has 65 employees.
The primary company behind Mono Pharmacare, Mono Pharmacare Limited, reported revenue of ₹166 Cr for FY 2026, down 2% year on year.
Mono Pharmacare was established in 2022 in Ahmedabad, India, within the pharmaceutical sector. Diversified drugs are distributed by the company to various healthcare providers and retailers. Operations focus on supply chain management and regulatory compliance in the Indian market. Services include procurement, storage, and timely delivery of essential medications. The domain monopharmacareltd.com supports online inquiries and business interactions.
Mono Pharmacare's top competitors include Entero Healthcare, Keimed and Sandor Medicaids.
Mono Pharmacare offers Antibiotic Medicines, Cough and Cold Medicines, Antifungal Medicines, Analgesic and Antipyretic Medicines, and Nutraceutical Products.
Yes, Mono Pharmacare is publicly traded on NSE under the ticker symbol MONOPHARMA.
Mono Pharmacare operates through Mono Pharmacare Limited.
The legal entities of Mono Pharmacare currently have 6 directors, including Panilam Lakhatariya, Supal Panilam Lakhatariya, Neha Chetan Prajapati and others.